| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
SARS-CoV-2-IN-14 targets SARS-CoV-2, likely through a mechanism similar to niclosamide, which inhibits viral entry and replication. As a niclosamide analogue, it may disrupt endosomal acidification or viral fusion. The compound has an IC50 of 0.39 μM against SARS-CoV-2. Its improved stability compared to niclosamide suggests a more favorable pharmacokinetic profile for oral administration.
|
|---|---|
| ln Vitro |
In vitro, SARS-CoV-2-IN-14 is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. It shows greater stability in human plasma and liver S9 enzyme assays than niclosamide, indicating improved metabolic stability. The compound is orally active, making it suitable for oral administration. It demonstrates significant antiviral activity.
|
| ln Vivo |
In vivo, SARS-CoV-2-IN-14 is expected to show improved bioavailability and half-life when administered orally compared to niclosamide, due to its greater stability in plasma and liver S9 fractions. However, specific in vivo efficacy data in animal models of SARS-CoV-2 infection are not extensively reported. The compound is a promising candidate for further development as an oral antiviral agent.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for SARS-CoV-2-IN-14 typically involve antiviral activity assays using Vero E6 cells infected with SARS-CoV-2. Cells are cultured in DMEM with 2% FBS and treated with various concentrations of the compound (typically 0.001-10 μM) for 48-72 hours. Viral replication is quantified by plaque assay or qRT-PCR. The IC50 is determined from dose-response curves. Metabolic stability is evaluated in human plasma and liver S9 fractions.
|
| Cell Assay |
In vitro cellular assays for SARS-CoV-2-IN-14 use Vero E6 cells or Calu-3 human lung epithelial cells infected with SARS-CoV-2. Cells are cultured in DMEM with 2% FBS and treated with various concentrations of the compound (typically 0.001-10 μM) for 48-72 hours post-infection. Viral RNA is quantified by RT-qPCR. Viral titers are determined by plaque assay. Cytotoxicity is assessed using CellTiter-Glo or MTT assays.
|
| Animal Protocol |
In vivo animal studies with SARS-CoV-2-IN-14 would typically use mouse models of SARS-CoV-2 infection (e.g., K18-hACE2 transgenic mice). Mice are infected intranasally with SARS-CoV-2 and treated with the compound orally at doses of 1-50 mg/kg, once or twice daily for 3-7 days. Viral load in lungs and other tissues is measured by qRT-PCR. Lung histopathology, cytokine levels, and survival are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of SARS-CoV-2-IN-14: The compound shows greater stability in human plasma and liver S9 enzyme assays than niclosamide, which can improve oral bioavailability and half-life. Specific PK parameters are not extensively reported. The compound has a molecular weight of 282.12.
|
| Toxicity/Toxicokinetics |
The toxicity profile of SARS-CoV-2-IN-14 is not extensively reported. As a niclosamide analogue, it may have a similar safety profile to niclosamide. The compound is for research use only and not for human therapeutic use.
|
| References | |
| Additional Infomation |
SARS-CoV-2-IN-14 (CAS 22203-98-1, compound 6) is a potent, orally active inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. It is a niclosamide analogue that demonstrates greater stability in human plasma and liver S9 enzyme assays, potentially improving oral bioavailability and half-life. The compound is a promising candidate for research on COVID-19 therapeutics and is available for research use only.
|
| Molecular Formula |
C13H9NO2CL2
|
|---|---|
| Molecular Weight |
282.12206
|
| Exact Mass |
281.001
|
| CAS # |
22203-98-1
|
| PubChem CID |
20196
|
| Appearance |
White to off-white solid powder
|
| Density |
1.479g/cm3
|
| Boiling Point |
361.5ºC at 760 mmHg
|
| Flash Point |
172.4ºC
|
| Vapour Pressure |
9.91E-06mmHg at 25°C
|
| Index of Refraction |
1.685
|
| LogP |
4.024
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
301
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NXDGLRGDIKDWIF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H9Cl2NO2/c14-8-2-1-3-10(6-8)16-13(18)11-7-9(15)4-5-12(11)17/h1-7,17H,(H,16,18)
|
| Chemical Name |
5-chloro-N-(3-chlorophenyl)-2-hydroxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~886.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5446 mL | 17.7230 mL | 35.4459 mL | |
| 5 mM | 0.7089 mL | 3.5446 mL | 7.0892 mL | |
| 10 mM | 0.3545 mL | 1.7723 mL | 3.5446 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
